HIKAL
Hikal Limited (HIKAL) Stock Analysis
Hikal Limited is an Indian custom research and manufacturing company serving pharma and crop science customers. It produces APIs, intermediates, and animal health ingredients for global innovators. The company operates regulated manufacturing sites. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹213.70
-2.05% 1W | -9.20% 52W
Market Cap
2.6k CR
P/E Ratio
–
52W High
₹261
52W Low
₹146.2
Div. Yield
0.28%
Beta
0.6
50 DMA
₹220.2
200 DMA
₹203.5
Profit Margin
-1.9%
Inst. Own.
6.8%
📉 CONSOLIDATING DOWN
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 388.00 | 434.88 | 447.50 | 514.10 | 406.80 | 452.90 | 447.70 | 552.40 | 380.40 | 318.50 | 494.30 | 519.40 | 402.80 |
| Expenses | 337.70 | 377.36 | 382.80 | 419.70 | 348.80 | 378.00 | 375.60 | 429.00 | 355.30 | 311.30 | 411.60 | 414.00 | 365.80 |
| Operating Profit | 50.30 | 57.52 | 64.70 | 94.40 | 58.00 | 74.90 | 72.10 | 123.40 | 25.10 | 7.20 | 82.70 | 105.40 | 37.00 |
| OPM % | 12.96% | 13.23% | 14.46% | 18.36% | 14.26% | 16.54% | 16.10% | 22.34% | 6.60% | 2.26% | 16.73% | 20.29% | 9.19% |
| Other Income | 0.90 | 0.99 | 0.10 | 0.50 | 0.50 | 0.40 | 3.60 | 0.50 | 1.00 | 1.90 | -35.20 | -40.50 | 10.70 |
| Interest | 13.80 | 13.08 | 14.20 | 15.30 | 19.80 | 18.80 | 18.70 | 17.90 | 17.10 | 14.90 | 15.50 | 14.60 | 14.90 |
| Depreciation | 27.70 | 28.57 | 29.00 | 32.30 | 31.80 | 31.70 | 33.20 | 37.70 | 39.40 | 41.20 | 41.20 | 42.00 | 42.70 |
| Profit before tax | 9.70 | 16.86 | 21.60 | 47.30 | 6.90 | 24.80 | 23.80 | 68.30 | -30.40 | -47.00 | -9.20 | 8.30 | -9.90 |
| Tax % | 28.87% | 25.44% | 25.46% | 28.33% | 26.09% | 26.21% | 27.73% | 26.50% | -26.32% | -25.74% | -35.87% | -73.49% | -25.25% |
| Net Profit | 6.90 | 12.57 | 16.10 | 33.90 | 5.10 | 18.30 | 17.20 | 50.20 | -22.40 | -34.90 | -5.90 | 14.40 | -7.40 |
| EPS in Rs | 0.56 | 1.02 | 1.31 | 2.75 | 0.41 | 1.48 | 1.39 | 4.07 | -1.82 | -2.83 | -0.48 | 1.17 | -0.60 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 872 | 926 | 1,014 | 1,296 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 | 1,735 |
| Expenses | 689 | 745 | 813 | 1,054 | 1,291 | 1,234 | 1,398 | 1,602 | 1,765 | 1,518 | 1,531 | 1,492 | 1,503 |
| Operating Profit | 182 | 181 | 201 | 242 | 298 | 273 | 323 | 341 | 258 | 267 | 328 | 220 | 232 |
| OPM % | 21% | 20% | 20% | 19% | 19% | 18% | 19% | 18% | 13% | 15% | 18% | 13% | 13% |
| Other Income | 2 | 2 | -3 | 4 | 2 | -12 | 5 | 5 | 5 | 2 | 5 | -73 | -63 |
| Interest | 60 | 62 | 48 | 49 | 58 | 52 | 36 | 31 | 48 | 56 | 75 | 62 | 60 |
| Depreciation | 64 | 67 | 69 | 86 | 93 | 82 | 85 | 96 | 109 | 118 | 134 | 164 | 167 |
| Profit before tax | 60 | 53 | 80 | 112 | 149 | 127 | 206 | 219 | 105 | 96 | 124 | -78 | -58 |
| Tax % | 32% | 23% | 16% | 31% | 31% | 33% | 36% | 27% | 26% | 27% | 27% | -38% | |
| Net Profit | 40 | 41 | 68 | 77 | 103 | 84 | 133 | 160 | 78 | 70 | 91 | -49 | -34 |
| EPS in Rs | 3.28 | 3.34 | 5.49 | 6.26 | 8.36 | 6.85 | 10.80 | 13.02 | 6.36 | 5.64 | 7.36 | -3.96 | -2.74 |
| Dividend Payout % | 20% | 20% | 15% | 13% | 14% | 18% | 19% | 12% | 19% | 21% | 19% | -15% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -5.0% | 0.0% | 6.0% |
| Profit CAGR | -30.0% | -27.0% | -4.0% |
Shareholding Pattern
Promoters68.85%
FIIs5.35%
DIIs4.03%
Public21.76%
Promoters68.85%
FIIs4.23%
DIIs5.15%
Public21.75%
Promoters68.85%
FIIs2.31%
DIIs7.05%
Public21.78%
Promoters68.85%
FIIs1.44%
DIIs7.20%
Public22.51%
Promoters68.85%
FIIs0.98%
DIIs7.23%
Public22.92%
Promoters68.85%
FIIs4.56%
DIIs2.18%
Public24.40%
Promoters68.85%
FIIs6.55%
DIIs3.53%
Public21.06%
Promoters68.85%
FIIs5.70%
DIIs3.80%
Public21.65%
Promoters68.85%
FIIs1.44%
DIIs7.20%
Public22.51%
Promoters68.85%
FIIs0.98%
DIIs7.23%
Public22.92%
HIKAL
Holdings Analysis
Key strengths & risk signals
52
Overall
35
Fundamental
69
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (213.7) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.0% (1 week), 11.2% (1 month), 12.7% (3 months).
WEAK YEAR! Stock declined 9.2% in the last year.
Strengths (3)
BULLISH TREND! 50-day average (220.2) is above 200-day average (203.5) - positive signal.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 4,714,050 vs down days: 903,276. Ratio: 5.22x
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Fundamental & Technical Analysis
52Overall
35Fundamental
69Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -5.4% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -1.9% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.28% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 23.79% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (220.2) is above 200-day average (203.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (213.7) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
3/10
WEAK YEAR! Stock declined 9.2% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 4,714,050 vs down days: 903,276. Ratio: 5.22x
RSI
3/5
NEUTRAL! RSI at 46.1 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 58.8% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.0% (1 week), 11.2% (1 month), 12.7% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
HIKAL
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-12 | Concall PDF | |
| Q4FY262026-06-03 | Concall PDF | |
| Q3FY262026-02-17 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
| SAKAR | ₹1,011.50 | 72.3 | 13.3% | 22.0% | 23.0% | +184.6% | 78 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹23.30 | 24.8 | 17.2% | 29.4% | 56.2% | +38.7% | 84 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| SOLARA | ₹644.40 | – | -0.1% | -1.2% | – | +14.8% | 53 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹360.90 | 53.9 | 8.5% | -19.7% | -3.2% | +249.6% | 59 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
| INDOCO | ₹230.70 | 699.1 | 0.3% | 3.0% | – | -14.2% | 54 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| WINDLAS | ₹949.20 | 30.4 | 7.1% | 20.7% | 16.0% | +11.7% | 75 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
Data from TradeAlone · Updated daily
HIKAL News
Hikal Limited (hikal) Ventures into Personal Care: New CGMP Panoli Facility Begins Commercial Production2026-09-22Hikal Limited Q1 FY27: Revenue at Rs. 403 Crs with Ebitda Margin Expanding 260 Bps Yoy2026-08-06Hikal Limited Earns Ecovadis Gold Medal, Ranking in Top 5% Globally for Sustainability Performance2026-07-29Hikal Limited Q4 FY26: Revenue Up 10%, Ebitda Margin at 20.3%2026-05-27
